Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis
Benjamin Ng(National University of Singapore), Jinrui Dong(National University of Singapore), Giuseppe D’Agostino(National University of Singapore), Sivakumar Viswanathan(National University of Singapore), Anissa A. Widjaja(National University of Singapore), Wei‐Wen Lim(National University of Singapore), Nicole S. J. Ko(National University of Singapore), Jessie Tan(National University of Singapore), Sonia Chothani(National University of Singapore), Benjamin Huang(National University of Singapore), Chen Xie(National Heart Centre Singapore), Chee Jian Pua(National Heart Centre Singapore), Ann‐Marie Chacko(National University of Singapore), Nuno Guimarães‐Camboa(Goethe University Frankfurt), Sylvia Μ. Evans(University of California San Diego), Adam J. Byrne(Lung Institute), Toby M. Maher(Lung Institute), Jiurong Liang(Cedars-Sinai Medical Center), Dianhua Jiang(Cedars-Sinai Medical Center), Paul W. Noble(Cedars-Sinai Medical Center), Sebastian Schäfer(National University of Singapore), Stuart A. Cook(National University of Singapore)
Cited by 300
Abstract
)-deleted mice, whose lung fibroblasts are unresponsive to profibrotic stimulation, are protected from fibrosis in the bleomycin mouse model of pulmonary fibrosis. We generated an IL-11-neutralizing antibody that blocks lung fibroblast activation downstream of multiple stimuli and reverses myofibroblast activation. In therapeutic studies, anti-IL-11 treatment diminished lung inflammation and reversed lung fibrosis while inhibiting ERK and SMAD activation in mice. These data prioritize IL-11 as a drug target for lung fibrosis and IPF.
Related Papers
No related papers found
Powered by citation graph analysis